Latest Aeterna Zentaris Inc. Stories
QUÉBEC CITY, April 3, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Babette Aicher, PhD, Director of Preclinical Development, will be making a poster presentation on updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models, at the upcoming American Association for Cancer Research ("AACR") annual meeting, which will be...
All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 21, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2012. Key Developments in 2012 AEZS-108 (Doxorubicin Peptide Conjugate) -- Special Protocol Assessment...
QUEBEC CITY, March 12, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2012 financial and operating results on Thursday, March 21, 2013, after market close. The Company will host a conference call the next morning, Friday, March 22, 2013 at 8:30 a.m. (Eastern Time), to discuss these results. Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom"...
QUEBEC CITY, March 11, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an independent Data Safety Monitoring Board ("DSMB") has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade(®)) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Based on the outcome of its pre-planned interim analysis...
QUÉBEC CITY, Feb. 20, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a first patient has been treated for the randomized Phase 2 trial in chemotherapy refractory triple-negative ("ER/PR/HER2-negative") luteinizing hormone-releasing hormone receptor ("LHRH-R")-positive metastatic breast cancer, with the Company's targeted doxorubicin peptide conjugate, AEZS-108. Alberto J. Montero, MD, Assistant Professor, Department of...
NEW YORK, January 30, 2013 /PRNewswire/ -- Today, Traders Insight announced new research reports highlighting Immunomedics, Inc. (Nasdaq: IMMU), AEterna Zentaris Inc. (Nasdaq: AEZS), Rediff.com India Limited (Nasdaq: REDF), Century Aluminum Co. (Nasdaq: CENX) and Silicom Limited (Nasdaq: SILC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Immunomedics, Inc. Research...
QUÉBEC CITY, Dec. 28, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable...
Promising clinical response activity observed in patients with Hodgkin lymphoma QUÉBEC CITY, Dec. 11, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas. Furthermore, promising clinical response activity was observed in patients with classical Hodgkin...
QUÉBEC CITY, Dec. 4, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, MD, will be presenting a corporate overview at the Oppenheimer 23(rd) Annual Healthcare Conference on Thursday, December 13, 2012, at 9:25 am (Eastern), in the East Foyer of The Waldorf-Astoria Hotel in New York City. A live webcast of this presentation will be available on Aeterna...
QUÉBEC CITY, Nov. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that final Phase 2 data for perifosine, its oral AKT inhibitor, combined with sorafenib in patients with relapsed/refractory lymphomas, will be presented at the upcoming American Society of Hematology ("ASH") annual meeting in Atlanta, Georgia, December 8-11, 2012. Data will be disclosed during a poster presentation by Anna Guidetti, MD, of the Fondazione IRCCS Instituto...
